<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Hepatol Int</journal-id><journal-id journal-id-type="iso-abbrev">Hepatol Int</journal-id><journal-title-group><journal-title>Hepatology International</journal-title></journal-title-group><issn pub-type="ppub">1936-0533</issn><issn pub-type="epub">1936-0541</issn><publisher><publisher-name>Springer India</publisher-name><publisher-loc>New Delhi</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7136311</article-id><article-id pub-id-type="publisher-id">10026</article-id><article-id pub-id-type="doi">10.1007/s12072-020-10026-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of antiviral therapy for HBV in different trimesters of pregnancy: systematic review and network meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wu</surname><given-names>Yuchao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Liu</surname><given-names>Jinfeng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Feng</surname><given-names>Yali</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Shan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ji</surname><given-names>Fanpu</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ge</surname><given-names>Long</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Yao</surname><given-names>Naijuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Xufei</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Yingren</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chen</surname><given-names>Yaolong</given-names></name><address><email>sinograde@163.com</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yang</surname><given-names>Yuan</given-names></name><address><email>xayanyuan@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4823-9507</contrib-id><name><surname>Chen</surname><given-names>Tianyan</given-names></name><address><email>chentianyan@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.452438.c</institution-id><institution>Department of Infection Disease and Hepatopathy, </institution><institution>First Affiliated Hospital of Xi&#x02019;an Jiaotong University, </institution></institution-wrap>Xi&#x02019;an, 710061 Shaanxi China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.452672.0</institution-id><institution>Department of Infection Disease and Hepatopathy, </institution><institution>Second Affiliated Hospital of Xi&#x02019;an Jiaotong University, </institution></institution-wrap>Xi&#x02019;an, Shaanxi China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.32566.34</institution-id><institution-id institution-id-type="ISNI">0000 0000 8571 0482</institution-id><institution>Evidence-Based Medicine Center, Basic Medical Sciences, </institution><institution>Lanzhou University, </institution></institution-wrap>Lanzhou, China </aff><aff id="Aff4"><label>4</label>WHO Collaborating Centre for Guideline Implementation and Knowledge Translation, Lanzhou, China </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>3</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>3</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2020</year></pub-date><volume>14</volume><issue>2</issue><fpage>180</fpage><lpage>189</lpage><history><date date-type="received"><day>25</day><month>11</month><year>2019</year></date><date date-type="accepted"><day>21</day><month>2</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Several antiviral agents licenced for blocking mother-to-child transmission (MTCT) of HBV, but their relative efficacy beginning from <italic>different trimesters</italic> has scarce been evaluated. We aimed to conduct a network meta-analysis to statistically differ the efficacy and safety of each antiviral agents initiating on different timings in preventing mother-to-infant transmission of HBV.</p></sec><sec><title>Methods</title><p id="Par2">Studies were included from PubMed, EMBASE, Web of Science, and Cochrane databases through July 1, 2019. Eligible studies recruited randomized controlled trials and nonrandomized studies reporting about infant or/and maternal efficacy and safety outcomes and were screened by two investigators independently. Extracted data were analyzed by pair-wised and network meta-analysis, respectively.</p></sec><sec><title>Results</title><p id="Par3">3 Randomized and 32 nonrandomized studies enrolling 6738 pregnant female were included. Using network analysis, any antiviral agent interrupted HBV vertical transmission much more effectively than placebo. No agent showed significant efficacy different from others, but a strong trend toward significance was found in telbivudine and tenofovir, of which had the highest probability of being ranked the first- or second-best treatment for reducing MTCT of HBV. The treatment applied in the first and second trimester had a similar efficacy in preventing MTCT. Compared with the initiation during the third trimester, lower rate of MTCT was revealed when antiviral therapy was administrated before third trimester, (RR&#x02009;=&#x02009;0.045, 95% CI 0.0053 to 0.20); a similar effect at delivery on suppressing maternal HBV DNA level and converting serum HBeAg were achieved if the timing of antiviral treatment started prior, but an obvious improvement of normalizing ALT flare was calculated out; no statistically differences among maternal and fetal safety outcomes were found if mothers received antiviral agents before pregnant 28&#x000a0;weeks.</p></sec><sec><title>Conclusion</title><p id="Par4">This network meta-analysis recommended the earlier use of telbivudine or tenofovir, tends to be better to prevent MTCT of HBV in pregnancy with no increased adverse maternal or fetal outcomes.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1007/s12072-020-10026-0) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hepatitis B</kwd><kwd>Mother-to-child transmission</kwd><kwd>Pregnancy</kwd><kwd>Antiviral treatment</kwd><kwd>Network meta-analysis</kwd><kwd>Lamivudine</kwd><kwd>Telbivudine</kwd><kwd>Tenofovir</kwd><kwd>Efficacy</kwd><kwd>Safety outcomes</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100014718</institution-id><institution>Innovative Research Group Project of the National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81670537</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Jinfeng</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100013317</institution-id><institution>Shanxi Provincial Key Research and Development Project</institution></institution-wrap></funding-source><award-id>S2018-YF-ZDSF-0240</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Tianyan</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>National Science and Technology Projects on Major Infectious Diseases</institution></funding-source><award-id>2017ZX10202202-002-006</award-id><principal-award-recipient><name><surname>Zhao</surname><given-names>Yingren</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Asian Pacific Association for the Study of the Liver 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Perinatal or intrauterine transmission is the major risk of transmission of HBV in its area of high endemicity [<xref ref-type="bibr" rid="CR1">1</xref>]. Since the last decades, hepatitis B vaccination and immunoglobulin administration provided at birth have been implemented to prevent vertical transmission of HBV [<xref ref-type="bibr" rid="CR2">2</xref>]. However, 50 Mio. new cases of HBV infection are still diagnosed annually due to mother-to-child transmission, MTCT [<xref ref-type="bibr" rid="CR3">3</xref>]. High level of HBV DNA level (HBV&#x02009;&#x0003e;&#x02009;10<sup>6</sup>&#x000a0;IU/mL) and HBeAg positivity during reproductive years [<xref ref-type="bibr" rid="CR4">4</xref>] contribute to the high risk of transmission, particularly in Asian countries [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par6">Lamivudine (LAM), telbivudine (LDT), and tenofovir (TDF) are the oral anti-HBV drugs approved by FDA. All agents have been well investigated and show effective and safe in reducing the risk of HBV MTCT if pregnant female were carrying high viral load of HBV [<xref ref-type="bibr" rid="CR6">6</xref>]. Emerging data suggest the application of antiviral therapy in the third trimester is able to prevent immunoprophylaxis failure [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>] to a great extent. Currently, only scarce studies showed the rates of MTCT appeared similar under the utilization of agents during second and third trimester [<xref ref-type="bibr" rid="CR11">11</xref>], but the events of HBV transmission were still reported even if their mothers obtained a treatment in late pregnancy [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. The well efficacy and safety in preventing MTCT have been clearly investigated among highly viremic HBV of mothers that started antiviral therapy in the first or second trimesters [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Therefore, it&#x02019;s necessary to identify a more effective and safe period for initiating antiviral treatment (AVT) in pregnancy to completely prevent HBV transmission.</p><p id="Par7">Network meta-analysis is undoubtedly a better way to calculate the risk ratio of rare events. It allows to discriminate the interventions which are lack of head-to-head comparisons [<xref ref-type="bibr" rid="CR15">15</xref>] by indirect means. Thus, for our primary objective to identify the effective timing of starting AVT, network meta-analysis allowed us to make a distinction of the period between the early-middle pregnancy and late pregnancy on agent use in preventing perinatal transmission. Our secondary objectives were set to determine safety outcomes among different trimesters of treatment administration.</p></sec><sec id="Sec2"><title>Materials and methods</title><p id="Par8">See Supplementary Materials<bold>.</bold></p></sec><sec id="Sec3"><title>Results</title><sec id="Sec4"><title>Characterization and quality of studies</title><p id="Par9">The search strategy generated 6904 citations, 468 of which appeared to be relevant. We retrieved for detailed evaluation after removing records due to duplicated titles and abstracts. Other 10 articles were included by cross referencing. Among those 478 manuscripts, 443 were excluded for various reasons, and finally 35 controlled studies, including 3 RCTs and 32 nonrandomized studies, were selected. 6738 pregnant female were enrolled in our analysis (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). 28 in English and 7 in Chinese were fully published. Most of the studies (74%, 26/35) were conducted in China among pregnant female that started AVT across different trimesters because of a high viral load of HBV DNA. All infants received HBV vaccination and immunoglobulin at birth. Table S1 summarized the characterization of individual studies.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow diagram of study selection process in the systematic review</p></caption><graphic xlink:href="12072_2020_10026_Fig1_HTML" id="MO1"/></fig></p><p id="Par10">Among the selected studies, 3 RCTs [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>] and 12 non-RCTs [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>] compared treatment started in the third trimester versus control, 7 non-RCTs compared the timing of second trimester versus control [<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>], 3 non-RCTs compared first trimester versus control [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], 4 non-RCTs compared second and third trimester versus control respectively [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref>], 3 non-RCTs compared first, second trimester versus control respectively [<xref ref-type="bibr" rid="CR39">39</xref>&#x02013;<xref ref-type="bibr" rid="CR41">41</xref>]; 2 non-RCTs compared first, third trimester versus control respectively [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR42">42</xref>], 1 non-RCTs compared first, second trimester, third trimester versus control respectively [<xref ref-type="bibr" rid="CR13">13</xref>]. No randomized controlled trials were conducted for the treatment that was applied during first or second trimester except for several non-RCTs.</p><p id="Par11">Risk of biases for all included studies was presented in Tables S2 and S3. 3 RCTs were at low risk of bias. 81% (26/32) non-RCTs were assigned as low level of risk of bias according to the reports of adequate patient selection methods, comparable study groups, and adequate outcome measures as well as follow-up data.</p></sec><sec id="Sec5"><title>Efficacy for infant outcomes: pair-wised meta-analysis and network meta-analysis</title><sec id="Sec6"><title>Pair-wised meta-analysis</title><p id="Par12">We performed meta-analysis among pure RCTs and non-RCTs respectively, to obtain their specific grade evidence. Then we incorporated RCTs with non-RCTs data together for a pooled meta-analysis to find out the biased impact of RCTs or non-RCTs on the meta-analysis in the real world. We focused on the comparisons of following timing groups, including gestation&#x02009;~&#x02009;28&#x000a0;weeks and gestation 28&#x02013;32&#x000a0;weeks, and aimed to get a clear investigation about the optimal initial time point of AVT in reducing MTCT.</p><p id="Par13">Comparing with control group, conducting any antiviral drugs in early-middle pregnancy (21 non-RCTs; RR 0.06; 95% CI 0.03 to 0.10, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a) and late pregnancy (21 non-RCTs: RR 0.19; 95% CI 0.11 to 0.32, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b) were both associated with reduced the likelihood of MTCT, based on calculated ratio of HBsAg serum positivity or/and HBV DNA seropositivity for infants at 6&#x02013;12&#x000a0;months after delivery. AVT used prior late pregnancy although didn&#x02019;t have significant difference but tended to have in decreasing the rate of HBV vertical transmission, as compared with the treatment administrated in late pregnancy (RR, 0.25; 95% CI 0.03 to 2.32, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c). Utilization of any antiviral agents prior gestation 28&#x000a0;week and during 28&#x02013;32&#x000a0;week reduced the ratio of infected infants by 10.8% and 7.3%, respectively, compared to control. AVT during earlier trimester appeared to reduce the risk by 3.5% over the administration in late pregnancy. This means that the probability of AVT before the third trimester may be more effective in preventing MTCT. The quality of evidence was low and rated down due to the risk of bias in non-RCTs. When studies were pooled, there was no evidence of publication bias or other small-study effects (Fig. S1a, b), with Egger&#x02019;s test <italic>p</italic> value&#x02009;&#x0003e;&#x02009;0.05.<fig id="Fig2"><label>Fig. 2</label><caption><p>Forest plot of pair-wised meta-analysis of MTCT at 6&#x02013;12&#x000a0;months after delivery for non-RCTs. <bold>a</bold> Antiviral therapy&#x02009;~&#x02009;28&#x000a0;week versus control, <bold>b</bold> 28&#x02013;32&#x000a0;week versus control at 6&#x02013;12&#x000a0;months after delivery. <bold>c</bold>&#x02009;~&#x02009;28&#x000a0;week versus 28&#x02013;32&#x000a0;week</p></caption><graphic xlink:href="12072_2020_10026_Fig2a_HTML" id="MO2"/><graphic xlink:href="12072_2020_10026_Fig2b_HTML" id="MO20"/></fig></p><p id="Par14">We further performed a subgroup analysis from the timing of usage before the third trimester. As respected, either AVT at&#x02009;~&#x02009;14&#x000a0;weeks or between 14 and 28&#x000a0;weeks showed significant efficacy in interrupting MTCT separately when comparing with untreated pregnant female (Fig. S2a, b).</p></sec><sec id="Sec7"><title>Network meta-analysis</title><p id="Par15">Previous studies have indicated LAM, LDT and TDF have great efficacy on decreasing MTCT rate of HBV. At first, we integrated RCTs with non-RCTs to perform an overcalled Bayesian network analysis for the comparisons among the above three agents. To avoid the risk of bias of individual agent effect on the results, we conducted the following meta-analysis to descript the efficacy of different agents initiated in different trimesters on preventing HBV vertical transmission. The pooled network plots were provided in Fig. S3. Compared to untreated group, LAM, LDT and TDF all had significant improvement to reduce HBV transmission (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Though no agent showed significant efficacy different from others (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>), a strong trend toward significance was found in telbivudine and tenofovir, of which had the highest probability of being ranked the first- or second-best treatment for reducing MTCT of HBV (Figs. S4, S5). In addition, the detailed analysis indicated that the agents initiated either prior gestation 28&#x000a0;week or during 28&#x02013;32&#x000a0;week were superior than control group on reducing MTCT rates, but no agent was clearly superior to others (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Forest plot for network meta-analysis of MTCT of different agents initiated during pregnancy</p></caption><graphic xlink:href="12072_2020_10026_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><p>Forest plot for network meta-analysis of MTCT of different agents used <bold>a</bold> before third trimester and <bold>b</bold> in third trimester</p></caption><graphic xlink:href="12072_2020_10026_Fig4_HTML" id="MO4"/></fig></p><p id="Par16">Therefore, we continued to conduct the Bayesian network meta-analysis specially non-RCTs to obtain available GRAD evidence. The network and forest plots were provided in Figs. S6 and <xref rid="Fig5" ref-type="fig">5</xref>. As compared with the control group, pregnant female that received AVT either prior third trimester (32 non-RCTs: RR 0.0034; 95% CI 3.1E&#x02212;04 to&#x02009;&#x02212;&#x02009;0.014) or in the third trimester (32 non-RCTs: RR 0.10; 95% CI 0.035 to 0.21) got an improvement in preventing MTCT (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). The treatment applied in early-middle pregnancy obtained superior efficacy to that intervention starting in late pregnancy (32 non-RCTs: RR 0.033; 95% CI 0.0033 to 0.16, Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). We further synthesized multiple RCTs and non-RCTs for pooled analysis to evaluate the potential impact of RCTs on the results. The pooled analysis showed similar RR and 95% CI based on the network meta-analysis of pure non-RCTs (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><p>Forest plot for network meta-analysis of MTCT of any agents among different trimesters</p></caption><graphic xlink:href="12072_2020_10026_Fig5_HTML" id="MO5"/></fig></p><p id="Par17">To reveal whether giving agents in early or middle pregnancy produce a potential impact on the bias of meta-analysis, subgroup analysis demonstrated that timing of treatment in early pregnancy (32 non-RCTs: RR 0.0076; 95% CI 2.1E&#x02212;04 to 0.055), middle pregnancy (32 non-RCTs: RR 0.0015; 95% CI 3.7E&#x02212;05 to&#x02009;&#x02212;&#x02009;0.03) and late pregnancy (32 non-RCTs: RR 0.10; 95% CI 0.034 to 0.20) all had statistically significant reduction in MTCT at 6&#x02013;12&#x000a0;months after delivery than untreated mothers. The network and forest plots were provided in FigS. S7 and <xref rid="Fig6" ref-type="fig">6</xref>. No significant priority was suggested for the timing selection between second trimester (32 non-RCTs: 0.20; 95% CI 0.0036 to 10.1) and first trimester (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>) on decreasing HBV MTCT. However, AVT starting during the second trimester attached much more effect on preventing HBV vertical transmission than that in the third trimester (32 non-RCTs: 0.015; 95% CI 4.1E&#x02212;04 to&#x02009;&#x02212;&#x02009;0.13, Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). Treatments ranking probabilities, from largest to smallest, were as follows: second trimester, first trimester, third trimester, control (Fig. S8).<fig id="Fig6"><label>Fig. 6</label><caption><p>Forest plot for network meta-analysis of MTCT comparing any agents in first, second, third trimester versus control at 6&#x02013;12&#x000a0;months after delivery in non-RCTs</p></caption><graphic xlink:href="12072_2020_10026_Fig6_HTML" id="MO6"/></fig></p><p id="Par18">In addition, we conducted network meta-analysis among the studies enrolling HBeAg positive mothers. Among the HBeAg positive pregnant female received AVT treatment, initiation in middle pregnancy indicated an improved effect on reducing MTCT than initiation in late pregnancy (RR 2.7E&#x02212;18, 95% CI 6.0E&#x02212;55, 0.0081, Fig. S9).</p></sec></sec><sec id="Sec8"><title>Efficacy for maternal outcomes: network meta-analysis for non-RCTs</title><p id="Par19">We focused on the rate of HBV DNA suppression, HBeAg seroconvension and ALT normalization as the maternal efficacy outcomes. The forest plot for the Bayesian network meta-analysis was provided in Fig. S10. Comparing with the untreated group, intervening in earlier and late pregnancy both showed the significance of HBV DNA suppression, HBeAg seroconvension and ALT normalization. Comparing with the AVT initiated in late pregnancy, starting treatment in early-middle pregnancy had similar significant efficacy in HBV DNA suppressions (16 non-RCTs: RR 1.3; 95% CI 0.36 to 4.4), and HBeAg seroconversion (6 non-RCTs: RR 0.81; 95% CI 0.12 to 6.4). However, applying AVT in early-middle pregnancy suggested a better improvement in ALT normalization (11 non-RCTs: RR, 1.2; 95% CI 1.1 to 1.3) than in late pregnancy.</p></sec><sec id="Sec9"><title>Safety for infant outcomes: network meta-analysis for non-RCTs</title><p id="Par20">When comparing with the control group, administrating antiviral therapy prior or during the third trimester did not show clear difference from others on the incidence of congenital malformation rate, prematurity rate, Apgar scores&#x02009;&#x0003c;&#x02009;8, fetal death, and low birth weight (Fig. S11).</p></sec><sec id="Sec10"><title>Safety for maternal outcomes: network meta-analysis for non-RCTs</title><p id="Par21">When compared with control, conducting any antiviral therapy before or during the third trimester indicated no difference from others according to the incidence of postpartum hemorrhage, cesarean section, and elevated creatine kinase, gestational hypertension, membrane prerupture, oligohydramnios and polyhydramnios (Fig. S12).</p></sec><sec id="Sec11"><title>Quality of evidence</title><p id="Par22">The quality of the evidence about maternal and infant outcomes (Table S4) was low to very low due to the risk of bias and imprecision of nonrandomized controlled studies. We did not rate down any comparison for publication bias or indirectness.</p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par23">In this multiple-treatments meta-analysis of RCTs and nRCTs studies for the prevention of HBV viral MTCT, a comprehensive literature search was conducted with no restriction of publication date to ensure maximum coverage of existing studies. Two independent reviewers, Feng and Wu, conducted this research and included conference proceedings. The assessment of eligibility and data extraction were also performed in duplication by two independent reviewers. We subsequently contacted the authors of 5 other studies in which timing of agent application crossed gestation 28&#x000a0;weeks [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>], to obtain necessary data unable to get in original papers. However, we were not able to obtain required data from 3 studies that AVT was given on the timing of 24&#x02013;32 and 24&#x02013;36&#x000a0;week [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. We used a per-protocol analysis with a random-effects model to minimize the risk of MTCT that would be overestimated. Finally, we extracted and pooled maternal and infant outcomes, if reported, to provide a summary of safety data.</p><p id="Par24">Major clinical guidelines recommended the third trimester as the inception date due to inadequate evidence of safety in human data evaluated in an earlier pregnancy. Previous study has published that LDT administrated throughout early, middle, or late pregnancy is safe and effective to interrupt mother-to-infant transmission [<xref ref-type="bibr" rid="CR39">39</xref>]. Therefore, it needs to define optimal timing to initiate antiviral prophylaxis to completely prevent MTCT of HBV during pregnancy [<xref ref-type="bibr" rid="CR45">45</xref>].</p><p id="Par25">This network meta-analysis confirmed that administration of antiviral agents in early-middle pregnancy was associated with lower MTCT of HBV than the use in late pregnancy. LDT and TDF had a trend of prior use on reducing MTCT of HBV. Furthermore, starting treatment prior gestation 28&#x000a0;weeks was associated with enhancement of maternal ALT normalization at delivery. No significant differences in safety outcomes for both mothers and infants were found according to comparison with the treatment provided in the third trimester and control group.</p><p id="Par26">High viral load is independently associated with the high risk of HBV MTCT. For mothers at high risk, initiating MTCT in middle pregnancy, at least, can obtain adequate time to suppress the level of HBV DNA. In addition, the earlier administration is capable to control mothers&#x02019; liver function and decrease the risk of viral breakthrough during pregnancy. Current clinical guidelines reveal a range of HBV cutoff to prevent HBV transmission from 2&#x02009;&#x000d7;&#x02009;10<sup>5</sup> to 2&#x02009;&#x000d7;&#x02009;10<sup>7</sup>&#x000a0;IU/mL [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Amongst major studies, pregnant mothers were enrolled due to the high level of HBV DNA level (HBV DNA&#x02009;&#x0003e;&#x02009;6 log IU/mL). The average HBV DNA level was 7.074 (6.986, 7.161) log<sub>10</sub> IU/mL calculated by a random effect model (base characteristics of HBV DNA found in the Supplementary Material). However, we were unable to evaluate the effect on decreasing MTCT among the maternal HBV DNA level below 2&#x02009;&#x000d7;&#x02009;10<sup>5</sup>&#x000a0;IU/mL due to the lack of researches. In addition, among the HBeAg positive pregnant female received AVT treatment, initiation in middle pregnancy indicated an improved effect on reducing MTCT than initiation in late pregnancy. Accordingly, antiviral therapy should be at least provided to HBeAg positive pregnant mothers with high viral loads (&#x0003e;&#x02009;2&#x02009;&#x000d7;&#x02009;10<sup>6</sup>&#x000a0;IU/mL).</p><p id="Par27">Several systematic reviews and meta-analysis have been performed to evaluate the efficacy and safety of all the FDA-recommended antiviral agents including LAM, LDT and TDF in interrupting MTCT of HBV. Brown et al. recommended the use of these agents in female who are HBeAg positive and high level of HBV DNA in the third trimester to prevent MTCT [<xref ref-type="bibr" rid="CR6">6</xref>]. Another meta-analysis showed all recommended agents have a great effect on preventing vertical transmission of HBV and second trimester was the better timing of initiating AVT in the subgroup analysis of HBV DNA/HBsAg positivity [<xref ref-type="bibr" rid="CR48">48</xref>]. Major of them were based on the pair-wised meta-analysis [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Therefore, different from existing studies, our network analysis has some following remarkable characteristics. Firstly, conventional meta-analysis usually focused on pair-wised comparisons of two therapeutic measures, most of which contained controlled and untreated groups. The network meta-analysis was able to construct two or more interventions into a network structure, enabling overall computation of relative effectiveness from both direct one-to-one and indirect comparison with multiple interventions. Second, previous meta-analyses used the frequency method, which might reduce the accuracy of RR, to estimate relative risk for the rare events of HBV MTCT. Bayesian method and ranked probabilities were suitable to provide more precise RR for the rare event of MTCT. However, our analysis has some limitations. First, all the three RCTs were designed for pregnant patients during the third trimester, and none of RCTs were conducted for patients before the third trimester. No head-to-head RCTs identified the efficacy of antiviral drugs started among different trimesters that our analysis mainly coming from non-RCTs cannot comprehensively reflect antiviral efficacy and lower down the grade evidence of observation in the real-world. As most of the guidelines recommend starting AVT in the third trimester, so it is unethical to perform RCTs to compare early treatment during pregnancy with no treatment group in future. In addition, due to the rare event of HBV MTCT after antiviral therapy during pregnancy, conducting a randomized trial comparing antiviral therapy initiated in the second vs. third trimester will be logistically difficult (huge sample size required). Network meta-analysis could collect direct and indirect evidence of non-RCTs to reduce statistical power and uncertainty on ranking results, and be effectively closed to the facts in the real world. Second, because most of non-RCTs provided different intervals of timing for treatments, the quality of data on this crucial question was low because exact initial timing of antiviral therapy was not specified or the timing was provided as a wide range in many studies. Third, the distributions of patients and disease background exist with selective bias based on non-randomized studies. In addition, some studies were conducted many years ago that the definition of MTCT of HBV was mainly based on HBsAg seropositivity at 6&#x000a0;months after delivery and subdata (e.g. maternal and infant outcomes) were not completely collected. We cannot draw a statistically meaningful conclusion when we analyze those safety data due to the limitation of information.</p><p id="Par28">In summary, this network meta-analysis suggests AVT administered in each trimester from first to the second trimester appeared superior to prevent MTCT of HBV than the third trimester, for HBeAg positive pregnant mothers with high viral loads (&#x0003e;&#x02009;2&#x02009;&#x000d7;&#x02009;10<sup>6</sup>&#x000a0;IU/mL). The limited safety data regarded to maternal and infant outcomes demonstrated no significant increased risk of issues. Large comparative RCTs, particularly of the utilization of AVT in early pregnancy or/and the head-to-head trials are warranted to further establish optimum initial timing to completely block HBV MTCT.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec13"><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12072_2020_10026_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 2573 kb)</p></caption></media></supplementary-material></p></sec></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Yuchao Wu, Jinfeng Liu, and Yali Feng are joint first authors.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We were grateful to Jing Wang, Xiaoguang Dou and Gang Qin for providing us with extra data for their prospective studies.</p></ack><notes notes-type="author-contribution"><title>Author contribution</title><p>Guarantor of the article: TC had full access to all of the data in the study and guaranteed the integrity of the data and the accuracy of the data analysis. Study concept and design: YW, JL, YY, YC, YZ, TC. Acquisition, analysis and interpretation of data: YW, JL, YY, YF, NY, LG, TC. Drafting of the manuscript: YW, JL, YY, TC. Critical revision of the manuscript for important intellectual content: YW, JL, YF, LG, FJ, YC, YZ, TC. All authors have approved the final draft of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the National Natural Science Foundation of China (Grant Nos. 81770594 and 81670537) Shaanxi Key Research and Development Program (S2018-YF-ZDSF-0240), and the National Science and Technology Projects on Major Infectious Diseases (13th Five Year, China) (Project No. 2017ZX10202202-002-006). The programs of funders had no role in the design and conduct of study; collection, management, analysis and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p></notes><notes notes-type="ethics"><title>Compliance with ethical standards</title><notes notes-type="COI-statement"><title>Conflict of interest</title><p id="Par29">Yuchao Wu, Jinfeng Liu, Yali Feng, Shan Fu, Fanpu Ji, Long Ge, Naijuan Yao, Xufei Luo, Yingren Zhao, Yaolong Chen, Yuan Yang and Tianyan Chen declare that they have no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schweitzer</surname><given-names>A</given-names></name><name><surname>Horn</surname><given-names>J</given-names></name><name><surname>Mikolajczyk</surname><given-names>RT</given-names></name><name><surname>Krause</surname><given-names>G</given-names></name><name><surname>Ott</surname><given-names>JJ</given-names></name></person-group><article-title>Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013</article-title><source>Lancet (Lond Engl)</source><year>2015</year><volume>386</volume><fpage>1546</fpage><lpage>1555</lpage></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kane</surname><given-names>MA</given-names></name></person-group><article-title>Global status of hepatitis B immunisation</article-title><source>Lancet (Lond Engl)</source><year>1996</year><volume>348</volume><fpage>696</fpage></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchanan</surname><given-names>C</given-names></name><name><surname>Tran</surname><given-names>TT</given-names></name></person-group><article-title>Management of chronic hepatitis B in pregnancy</article-title><source>Clin Liver Dis</source><year>2010</year><volume>14</volume><fpage>495</fpage><lpage>504</lpage><?supplied-pmid 20638027?><pub-id pub-id-type="pmid">20638027</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lok</surname><given-names>AS</given-names></name><name><surname>Lai</surname><given-names>CL</given-names></name><name><surname>Wu</surname><given-names>PC</given-names></name><name><surname>Leung</surname><given-names>EK</given-names></name><name><surname>Lam</surname><given-names>TS</given-names></name></person-group><article-title>Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection</article-title><source>Gastroenterology</source><year>1987</year><volume>92</volume><fpage>1839</fpage><lpage>1843</lpage><?supplied-pmid 3569757?><pub-id pub-id-type="pmid">3569757</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livingston</surname><given-names>SE</given-names></name><name><surname>Simonetti</surname><given-names>JP</given-names></name><name><surname>Bulkow</surname><given-names>LR</given-names></name><etal/></person-group><article-title>Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F</article-title><source>Gastroenterology</source><year>2007</year><volume>133</volume><fpage>1452</fpage><lpage>1457</lpage><?supplied-pmid 17920063?><pub-id pub-id-type="pmid">17920063</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>RS</given-names><suffix>Jr</suffix></name><name><surname>McMahon</surname><given-names>BJ</given-names></name><name><surname>Lok</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis</article-title><source>Hepatology</source><year>2016</year><volume>63</volume><fpage>319</fpage><lpage>333</lpage><?supplied-pmid 26565396?><pub-id pub-id-type="pmid">26565396</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>WM</given-names></name><name><surname>Cui</surname><given-names>YT</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study</article-title><source>J Viral Hepat</source><year>2009</year><volume>16</volume><fpage>94</fpage><lpage>103</lpage><?supplied-pmid 19175878?><pub-id pub-id-type="pmid">19175878</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>CQ</given-names></name><name><surname>Duan</surname><given-names>Z</given-names></name><name><surname>Dai</surname><given-names>E</given-names></name><etal/></person-group><article-title>Tenofovir to prevent hepatitis B transmission in mothers with high viral load</article-title><source>N Engl J Med</source><year>2016</year><volume>374</volume><fpage>2324</fpage><lpage>2334</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1508660</pub-id><?supplied-pmid 27305192?><pub-id pub-id-type="pmid">27305192</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jourdain</surname><given-names>G</given-names></name><name><surname>Ngo-Giang-Huong</surname><given-names>N</given-names></name></person-group><article-title>Tenofovir versus placebo to prevent perinatal transmission of hepatitis B</article-title><source>N Engl J Med</source><year>2018</year><volume>378</volume><fpage>911</fpage><lpage>923</lpage><?supplied-pmid 29514030?><pub-id pub-id-type="pmid">29514030</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>CQ</given-names></name><name><surname>Pang</surname><given-names>Q</given-names></name><name><surname>Tian</surname><given-names>R</given-names></name><name><surname>Yan</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name></person-group><article-title>Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice</article-title><source>Hepatology</source><year>2014</year><volume>60</volume><issue>2</issue><fpage>468</fpage><lpage>476</lpage><?supplied-pmid 25187919?><pub-id pub-id-type="pmid">25187919</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>CQ</given-names></name><name><surname>Yi</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wan</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>YH</given-names></name><name><surname>Zhou</surname><given-names>MF</given-names></name></person-group><article-title>Lamivudine therapy during the second vs the third trimester for preventing transmission of chronic hepatitis B</article-title><source>J Viral Hepat</source><year>2017</year><volume>24</volume><fpage>246</fpage><lpage>252</lpage><?supplied-pmid 28025872?><pub-id pub-id-type="pmid">28025872</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>MH</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Prospective cohort study on the efficacy and safety of telbivudine used throughout pregnancy in blocking mother-to-child transmission of hepatitis B virus</article-title><source>J Viral Hepat</source><year>2017</year><volume>24</volume><issue>Suppl 1</issue><fpage>49</fpage><lpage>56</lpage><?supplied-pmid 29082650?><pub-id pub-id-type="pmid">29082650</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Yao</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy and safety of telbivudine in different trimesters of pregnancy with high viremia for interrupting perinatal transmission of hepatitis B virus</article-title><source>Hepatol Res Off J Jpn Soc Hepatol</source><year>2016</year><volume>46</volume><fpage>E181</fpage><lpage>E188</lpage></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>T</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><etal/></person-group><article-title>Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B</article-title><source>Hepatol Int</source><year>2018</year><volume>12</volume><fpage>118</fpage><lpage>125</lpage><?supplied-pmid 29344772?><pub-id pub-id-type="pmid">29344772</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cipriani</surname><given-names>A</given-names></name><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Geddes</surname><given-names>JR</given-names></name><name><surname>Salanti</surname><given-names>G</given-names></name></person-group><article-title>Conceptual and technical challenges in network meta-analysis</article-title><source>Ann Intern Med</source><year>2013</year><volume>159</volume><fpage>130</fpage><lpage>137</lpage><?supplied-pmid 23856683?><pub-id pub-id-type="pmid">23856683</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thilakanathan</surname><given-names>C</given-names></name><name><surname>Wark</surname><given-names>G</given-names></name><name><surname>Maley</surname><given-names>M</given-names></name><etal/></person-group><article-title>Mother-to-child transmission of hepatitis B: examining viral cut-offs, maternal HBsAg serology and infant testing</article-title><source>Liver Int Off J Int Assoc Study Liver</source><year>2018</year><volume>38</volume><fpage>1212</fpage><lpage>1219</lpage></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Safety and efficacy of telbivudine in late pregnancy to prevent mother-to-child transmission of hepatitis B virus: a multicenter prospective cohort study</article-title><source>J Viral Hepat</source><year>2018</year><volume>25</volume><fpage>429</fpage><lpage>437</lpage><?supplied-pmid 29193547?><pub-id pub-id-type="pmid">29193547</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samadi Kochaksaraei</surname><given-names>G</given-names></name><name><surname>Castillo</surname><given-names>E</given-names></name><name><surname>Osman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region</article-title><source>J Viral Hepat</source><year>2016</year><volume>23</volume><fpage>15</fpage><lpage>22</lpage><?supplied-pmid 26192022?><pub-id pub-id-type="pmid">26192022</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Lee</surname><given-names>CN</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus</article-title><source>Hepatology</source><year>2015</year><volume>62</volume><fpage>375</fpage><lpage>386</lpage><?supplied-pmid 25851052?><pub-id pub-id-type="pmid">25851052</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenup</surname><given-names>AJ</given-names></name><name><surname>Tan</surname><given-names>PK</given-names></name><name><surname>Nguyen</surname><given-names>V</given-names></name><etal/></person-group><article-title>Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus</article-title><source>J Hepatol</source><year>2014</year><volume>61</volume><fpage>502</fpage><lpage>507</lpage><?supplied-pmid 24801414?><pub-id pub-id-type="pmid">24801414</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayres</surname><given-names>A</given-names></name><name><surname>Yuen</surname><given-names>L</given-names></name><name><surname>Jackson</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations</article-title><source>J Viral Hepat</source><year>2014</year><volume>21</volume><fpage>809</fpage><lpage>817</lpage><?supplied-pmid 24329944?><pub-id pub-id-type="pmid">24329944</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>LJ</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients</article-title><source>Chin J Hepatol</source><year>2009</year><volume>17</volume><fpage>561</fpage><lpage>563</lpage></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Effect of high viral hepatitis B virus DNA loads on vertical transmission of hepatitis B virus in late-pregnant women</article-title><source>Zhonghua fu chan ke za zhi</source><year>2008</year><volume>43</volume><fpage>329</fpage><lpage>331</lpage><?supplied-pmid 18953863?><pub-id pub-id-type="pmid">18953863</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Zonneveld</surname><given-names>M</given-names></name><name><surname>van Nunen</surname><given-names>AB</given-names></name><name><surname>Niesters</surname><given-names>HG</given-names></name><name><surname>de Man</surname><given-names>RA</given-names></name><name><surname>Schalm</surname><given-names>SW</given-names></name><name><surname>Janssen</surname><given-names>HL</given-names></name></person-group><article-title>Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection</article-title><source>J Viral Hepat</source><year>2003</year><volume>10</volume><fpage>294</fpage><lpage>297</lpage><?supplied-pmid 12823596?><pub-id pub-id-type="pmid">12823596</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>XM</given-names></name><name><surname>Yang</surname><given-names>YB</given-names></name><name><surname>Hou</surname><given-names>HY</given-names></name><etal/></person-group><article-title>Interruption of HBV intrauterine transmission: a clinical study</article-title><source>World J Gastroenterol</source><year>2003</year><volume>9</volume><fpage>1501</fpage><lpage>1503</lpage><?supplied-pmid 12854150?><pub-id pub-id-type="pmid">12854150</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>BA</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>XF</given-names></name><name><surname>Miao</surname><given-names>MF</given-names></name><name><surname>Zhu</surname><given-names>LH</given-names></name><name><surname>Yu</surname><given-names>HY</given-names></name></person-group><article-title>Evaluation of the efficacy and safety of telbivudine in preventing mother-to-infant HBV transmission</article-title><source>Chin Pharm J</source><year>2012</year><volume>47</volume><fpage>855</fpage><lpage>857</lpage></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>QJ</given-names></name><name><surname>Wang</surname><given-names>SJ</given-names></name><name><surname>Wu</surname><given-names>YY</given-names></name><name><surname>Dou</surname><given-names>XG</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name></person-group><article-title>Hepatitis B virus serosurvey and awareness of mother-to-child transmission among pregnant women in Shenyang, China: an observational study</article-title><source>Medicine</source><year>2018</year><volume>97</volume><fpage>e10931</fpage><?supplied-pmid 29851831?><pub-id pub-id-type="pmid">29851831</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>G</given-names></name><etal/></person-group><article-title>Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><fpage>15514</fpage><?supplied-pmid 30341345?><pub-id pub-id-type="pmid">30341345</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celen</surname><given-names>MK</given-names></name><name><surname>Mert</surname><given-names>D</given-names></name><name><surname>Ay</surname><given-names>M</given-names></name><etal/></person-group><article-title>Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection</article-title><source>World J Gastroenterol</source><year>2013</year><volume>19</volume><fpage>9377</fpage><lpage>9382</lpage><?supplied-pmid 24409065?><pub-id pub-id-type="pmid">24409065</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>ML</given-names></name><name><surname>Xu</surname><given-names>HT</given-names></name><name><surname>Ju</surname><given-names>HF</given-names></name><name><surname>Xian</surname><given-names>JC</given-names></name><name><surname>Yang</surname><given-names>XZ</given-names></name></person-group><article-title>Sequential telbivudine/lamivudine and hepatitis B immunoglobulin therapy for preventing mother-to-infant transmission of hepatitis B virus</article-title><source>World Chin J Digestol</source><year>2016</year><volume>24</volume><fpage>3517</fpage><lpage>3522</lpage></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>T</given-names></name><etal/></person-group><article-title>Efficacy and safety of telbivudine and tenofovir disoproxil fumarate in preventing hepatitis B vertical transmission: a real-life practice</article-title><source>J Viral Hepat</source><year>2019</year><volume>26</volume><fpage>1170</fpage><lpage>1177</lpage><?supplied-pmid 31177596?><pub-id pub-id-type="pmid">31177596</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>H</given-names></name></person-group><article-title>Effectiveness of tenofovir or telbivudine in preventing HBV vertical transmission for pregnancy</article-title><source>Medicine</source><year>2019</year><volume>98</volume><fpage>e15092</fpage><?supplied-pmid 30946367?><pub-id pub-id-type="pmid">30946367</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>BF</given-names></name><name><surname>Cheng</surname><given-names>ML</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Clinical study on blocking mother-to-child transmission of hepatitis B virus with high viral load and HBeAg positivity during pregnancy in Guizhou Province</article-title><source>Chin J Hepatol</source><year>2018</year><volume>26</volume><fpage>945</fpage><lpage>950</lpage></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Tu</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Clinical observation of telbivudine&#x02019;s antiviral efficacy and protection against mother-to-infant transmission of chronic hepatitis B during the first trimester of pregnancy</article-title><source>Chin J Hepatol</source><year>2015</year><volume>23</volume><fpage>9</fpage><lpage>12</lpage></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name></person-group><article-title>Long-term efficacy and safety of telbivudine in the treatment of childbearing patients with chronic hepatitis B</article-title><source>Chin J Hepatol</source><year>2014</year><volume>22</volume><fpage>573</fpage><lpage>576</lpage></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>GR</given-names></name><name><surname>Jiang</surname><given-names>HX</given-names></name><name><surname>Yue</surname><given-names>X</given-names></name><etal/></person-group><article-title>Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection</article-title><source>J Viral Hepat</source><year>2015</year><volume>22</volume><fpage>754</fpage><lpage>762</lpage><?supplied-pmid 25641421?><pub-id pub-id-type="pmid">25641421</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>ZX</given-names></name><name><surname>Gu</surname><given-names>GF</given-names></name><name><surname>Bian</surname><given-names>ZL</given-names></name><etal/></person-group><article-title>Clinical course and perinatal transmission of chronic hepatitis B during pregnancy: a real-world prospective cohort study</article-title><source>J Infect</source><year>2017</year><volume>75</volume><fpage>146</fpage><lpage>154</lpage><?supplied-pmid 28551372?><pub-id pub-id-type="pmid">28551372</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>Q</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><etal/></person-group><article-title>Efficacy and safety of nucleos(t)ide analogues to prevent hepatitis B virus mother-to-child transmission in pregnant women with high viremia: real life practice from China</article-title><source>Int J Med Sci</source><year>2018</year><volume>15</volume><fpage>796</fpage><lpage>801</lpage><?supplied-pmid 30008589?><pub-id pub-id-type="pmid">30008589</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><etal/></person-group><article-title>Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission</article-title><source>BMC Gastroenterol</source><year>2017</year><volume>17</volume><fpage>51</fpage><?supplied-pmid 28407735?><pub-id pub-id-type="pmid">28407735</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>Z</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Hou</surname><given-names>H</given-names></name></person-group><article-title>Telbivudine treatment of hepatitis B virus-infected pregnant women at different gestational stages for the prevention of mother-to-child transmission: outcomes of telbivudine treatment during pregnancy</article-title><source>Medicine</source><year>2016</year><volume>95</volume><fpage>e4847</fpage><?supplied-pmid 27749537?><pub-id pub-id-type="pmid">27749537</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Hao</surname><given-names>A</given-names></name><etal/></person-group><article-title>Predictive value of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women with high viremia</article-title><source>Chin J Hepatol</source><year>2015</year><volume>23</volume><fpage>180</fpage><lpage>183</lpage></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foaud</surname><given-names>HM</given-names></name><name><surname>Maklad</surname><given-names>S</given-names></name><name><surname>Gmal El Din</surname><given-names>A</given-names></name><name><surname>Mahmoud</surname><given-names>F</given-names></name></person-group><article-title>Lamivudine use in pregnant HBsAg-females effectively reduces maternal viremia</article-title><source>Arab J Gastroenterol Off Publ Pan-Arab Assoc Gastroenterol</source><year>2019</year><volume>20</volume><fpage>8</fpage><lpage>13</lpage></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><etal/></person-group><article-title>The safety of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women after discontinuation</article-title><source>Chin J Hepatol</source><year>2015</year><volume>23</volume><fpage>586</fpage><lpage>589</lpage></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><etal/></person-group><article-title>Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study</article-title><source>Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc</source><year>2015</year><volume>13</volume><fpage>1170</fpage><lpage>1176</lpage></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>CQ</given-names></name><name><surname>Lee</surname><given-names>HM</given-names></name></person-group><article-title>Antiviral therapy for chronic hepatitis B in pregnancy</article-title><source>Semin Liver Dis</source><year>2013</year><volume>33</volume><fpage>138</fpage><lpage>146</lpage><?supplied-pmid 23749670?><pub-id pub-id-type="pmid">23749670</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Cui</surname><given-names>F</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Management algorithm for interrupting mother-to-child transmission of hepatitis B virus</article-title><source>Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc</source><year>2019</year><volume>17</volume><fpage>1929</fpage><lpage>1936.e1</lpage></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Wen</surname><given-names>WH</given-names></name><name><surname>Chang</surname><given-names>MH</given-names></name></person-group><article-title>Management of pregnant women and children: focusing on preventing mother-to-infant transmission</article-title><source>J Infect Dis</source><year>2017</year><volume>216</volume><fpage>S785</fpage><lpage>S791</lpage><?supplied-pmid 29156049?><pub-id pub-id-type="pmid">29156049</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus: a meta-analysis</article-title><source>J Viral Hepat</source><year>2019</year><volume>26</volume><fpage>397</fpage><lpage>406</lpage><?supplied-pmid 30417469?><pub-id pub-id-type="pmid">30417469</pub-id></element-citation></ref></ref-list></back></article>